Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
59.90
-0.59 (-0.98%)
At close: Oct 30, 2026, 4:00 PM EDT
59.75
-0.15 (-0.25%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $75.25M in the quarter ending June 30, 2026, with 171.02% growth. This brings the company's total for the last twelve months to $669.50M, up 16.85% year-over-year. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth. That makes Arrowhead Pharmaceuticals the 9,639th largest company in the world by revenue and 2,099th in the United States.
Revenue (ttm)
$669.50M
Revenue Growth
+16.85%
P/S Ratio
12.64
Revenue / Employee
$941,624
Employees
711
Market Cap
8.46B
Revenue by Segment
- Sarepta 696.80M 84.0%
- Sanofi 130.00M 15.7%
- GSK 2.65M 0.3%
Fiscal year ended Sep 30, 2025 See the full Arrowhead Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
| Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
| Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| Corcept Therapeutics | 830.81M |
| TG Therapeutics | 799.54M |
| Axsome Therapeutics | 776.57M |
| Twist Bioscience | 431.80M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Cytokinetics | 67.67M |
ARWR News
- 5 days ago - Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides - Business Wire
- 18 days ago - Arrowhead assumed with a Buy at UBS - TheFly
- 18 days ago - Arrowhead Pharmaceuticals Transcript: Study update - Transcripts
- 18 days ago - Arrowhead Pharmaceuticals Slides: Study update - Filings
- 18 days ago - Arrowhead Pharmaceuticals Press release: Study update - Filings
- 18 days ago - Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT - TheFly
- 18 days ago - Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers - Business Wire
- 25 days ago - Arrowhead announces US FDA granted plozasiran entry into STAR program - TheFly